TransMedics Group (NASDAQ:TMDX) Price Target Increased to $117.00 by Analysts at Canaccord Genuity Group

TransMedics Group (NASDAQ:TMDX) had its price objective upped by Canaccord Genuity Group from $102.00 to $117.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the company. Piper Sandler restated an overweight rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research note on Wednesday. Oppenheimer increased their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an overweight rating in a report on Wednesday. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an equal weight rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $119.00.

TransMedics Group Trading Up 24.9 %

TMDX stock opened at $117.60 on Wednesday. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group has a 1 year low of $36.42 and a 1 year high of $124.18. The stock has a 50-day simple moving average of $83.85 and a 200-day simple moving average of $75.92.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. During the same quarter last year, the firm earned ($0.08) EPS. TransMedics Group’s quarterly revenue was up 132.9% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group will post -0.14 EPS for the current year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,047,155.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Waleed H. Hassanein sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,047,155.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 7,157 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the transaction, the director now directly owns 8,350 shares of the company’s stock, valued at $721,273. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,078 shares of company stock valued at $8,691,221. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new position in TransMedics Group in the 1st quarter worth approximately $30,000. Cutler Group LLC CA grew its holdings in TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after buying an additional 600 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after buying an additional 222 shares in the last quarter. RiverPark Advisors LLC bought a new position in TransMedics Group in the 3rd quarter worth approximately $60,000. Finally, Van ECK Associates Corp grew its holdings in TransMedics Group by 39.0% in the 3rd quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock worth $116,000 after buying an additional 597 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.